ArticleBlood2018
Glutaminolysis is a metabolic dependency in FLT3
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 149 citations in OpenAlex.
- Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial.Nature communications · 2026Trial
- Intrinsic and niche-dependent metabolic regulation of haematopoietic stem cells and implications for leukaemogenesis.Nature cell biology · 2026Review
- Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.Blood · 2026Article
- BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia.bioRxiv : the preprint server for biology · 2026Article
- Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.Blood · 2025Article
- Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia.Science advances · 2025Article
- Metabolic Signature ofJournal of personalized medicine · 2025Review
- SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells.Leukemia · 2025Article
- Metabolomic Profiling and Bioanalysis of Chronic Myeloid Leukemia: Identifying Biomarkers for Treatment Response and Disease Monitoring.Metabolites · 2025Article
- WNK1 signalling regulates amino acid transport and mTORC1 activity to sustain acute myeloid leukaemia growth.Nature communications · 2025Article
- Review
- Mapping of Functional Metabolic Phenotypes in Acute Myeloid Leukemia.Cancer medicine · 2025Article
- Targeting oncogenic activation of FLT3/SREBP/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids.Cell death & disease · 2025Article
- Genome-wide CRISPR/Cas9 screen identifies AraC-daunorubicin-etoposide response modulators associated with outcomes in pediatric AML.Blood advances · 2025Article
- Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions.International journal of molecular sciences · 2024Review
- Review
- Feasibility and Safety of Targeting Mitochondria Function and Metabolism in Acute Myeloid Leukemia.Current pharmacology reports · 2024Article
- Article
- A succinylation switch to maligancy: SUCLG1, mitochondrial transcription and leukemia.The EMBO journal · 2024Article
- SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression.The EMBO journal · 2024Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 3 institutions in 1 country.
Paolo GallipoliWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.ORCID 0000-0001-7254-2253
George GiotopoulosWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.
Konstantinos TzelepisHaematological Cancer Genetics, Wellcome Trust Sanger Institute-Hinxton, Cambridge, United Kingdom.
Ana S H CostaMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom; and.
Shabana VohraWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.
Paula Medina-PerezMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, United Kingdom.
Faisal BasheerWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.
Ludovica MarandoWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.
Lorena Di LisioDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.
Joao M L DiasDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.
Haiyang YunWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.
Daniel SascaWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.
Sarah J HortonWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.
George VassiliouDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.
Christian FrezzaMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom; and.
Brian J P HuntlyWellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.ORCID 0000-0003-0312-161X
Wellcome/MRC Cambridge Stem Cell Institute · GBUniversity of Cambridge · GBWellcome Sanger Institute · GB
Funding
Cancer Research UK 21617Cancer Research UK 23015Cancer Research UK 25508Cancer Research UK C56179/A21617Medical Research Council G1000288Medical Research Council MC_PC_12009Medical Research Council MC_UU_12022/6Medical Research Council MR/M010392/1Medical Research Council MR/R009708/1Wellcome TrustWellcome Trust 109967/Z/15/ZWorldwide Cancer Research 14-1069
Abstract
FLT3 internal tandem duplication (FLT3
Indexed as
fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationCRISPR-Cas SystemsEnzyme ActivationGenome-Wide Association StudyGlutamineHumansK562 CellsProtein Kinase InhibitorsTHP-1 CellsFLT3 protein, humanfms-Like Tyrosine Kinase 3GlutamineProtein Kinase Inhibitors
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.